Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Dasatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.